

Nicholas J. Santoro (Nev. Bar No. 532)  
 Jason D. Smith (Nev. Bar No. 9691)  
**SANTORO WHITMIRE, LTD.**  
 10100 W. Charleston Blvd., Suite 250  
 Las Vegas, NV 89135  
 Tel.: (702) 948-8771 / Fax: (702) 948-8773  
 E-mail: nsantoro@santoronevada.com,  
 jsmith@santoronevada.com

Christopher N. Sipes (admitted *pro hac vice*)  
 Einar Stole (admitted *pro hac vice*)  
 Michael N. Kennedy (admitted *pro hac vice*)  
 Megan P. Keane (admitted *pro hac vice*)  
 Eric R. Sonnenschein (admitted *pro hac vice*)  
 Alaina M. Whitt (admitted *pro hac vice*)  
**COVINGTON & BURLING LLP**  
 One CityCenter, 850 Tenth Street, NW  
 Washington, DC 20001  
 Tel.: (202) 662-6000 / Fax: (202) 662-6291  
 E-mail: csipes@cov.com, estole@cov.com,  
 mkennedy@cov.com, mkeane@cov.com,  
 esonnenschein@cov.com, awhitt@cov.com

*Attorneys for Plaintiffs Amarin Pharma, Inc. and  
 Amarin Pharmaceuticals Ireland Limited*

**UNITED STATES DISTRICT COURT  
 DISTRICT OF NEVADA**

AMARIN PHARMA, INC. and AMARIN  
 PHARMACEUTICALS IRELAND LIMITED,

Plaintiffs,

v.

TEVA PHARMACEUTICALS USA, INC.

Defendant.

Case No.: 2:16-cv-02525-MMD-NJK

(Consolidated with 2:16-cv-02562-MMD-NJK,  
 2:16-cv-02658-MMD-NJK, and 2:17-cv-02641-  
 MMD-NJK)

**CONSENT JUDGMENT**

Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited (hereinafter collectively  
 “Amarin”), and Teva Pharmaceuticals USA, Inc. (hereinafter “Teva”), the parties in the above-  
 captioned actions, have agreed to terms and conditions representing a negotiated settlement of the  
 actions and have set forth those terms and conditions in a Settlement Agreement (the “Settlement

1 Agreement”). Now the parties, by their respective undersigned attorneys, hereby stipulate and  
2 consent to entry of judgment and an injunction in the actions, as follows:

3 ORDERED, ADJUDGED AND DECREED as follows:

4 This District Court has jurisdiction over the subject matter of the above actions and has  
5 personal jurisdiction over the parties.

6 As used in this Consent Judgment, the terms “Teva Product,” “Approved Vacepa Product,”  
7 “Generic Icosapent Ethyl Product,” “Licensed Patents,” and “Affiliate” shall have the meanings  
8 assigned to them in the Settlement Agreement.

9 Teva admits that the Teva Product infringes the Licensed Patents and that the Licensed  
10 Patents and all the claims contained therein are each valid and enforceable in all respects. This  
11 admission is without prejudice to any claim, defense or counterclaim (including non-infringement,  
12 invalidity, unenforceability and unpatentability) in any future action regarding both (a) the Licensed  
13 Patents and (b) a product other than a Generic Icosapent Ethyl product and other than the Teva  
14 Product.

15 Unless otherwise specifically authorized pursuant to the Settlement Agreement, Teva,  
16 including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed  
17 Patents, on its own part or through any Affiliate, by making, having made, using, selling, offering to  
18 sell, importing or distributing of the Teva Product.

19 Unless otherwise specifically authorized pursuant to the Settlement Agreement, Teva is  
20 hereby enjoined and estopped during the term of each of the Licensed Patents from making any  
21 challenge to the validity or enforceability of the Licensed Patents and from asserting that the Teva  
22 Product does not infringe any of the Licensed Patents. Amarin acknowledges that Teva is entitled  
23 to maintain its Paragraph IV certification to the Licensed Patents with respect to the Teva Product  
24 pursuant to 21 C.F.R. § 314.94(a)(12)(v).

25 This Consent Judgment does not impact the U.S. Food and Drug Administration’s ability to  
26 grant final approval of the Teva Product at any time.

Compliance with this Consent Judgment may be enforced by Amarin and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement.

This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.

All claims, counterclaims, affirmative defenses and demands in these actions are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party.

IT IS SO ORDERED:

  
UNITED STATES DISTRICT JUDGE

Dated: May 25, 2018

We hereby consent to the form and entry of this Order:

/s/ Jason D. Smith  
Nicholas J. Santoro (Nev. Bar No. 532)  
Jason D. Smith (Nev. Bar No. 9691)  
SANTORO WHITMIRE, LTD.  
10100 W. Charleston Blvd., Suite 250  
Las Vegas, NV 89135  
Tel.: (702) 948-8771 / Fax: (702) 948-8773  
Email: nsantoro@santoronevada.com,  
jsmith@santoronevada.com

Christopher N. Sipes (admitted *pro hac vice*)  
Einar Stole (admitted *pro hac vice*)  
Michael N. Kennedy (admitted *pro hac vice*)  
Megan P. Keane (admitted *pro hac vice*)  
Eric R. Sonnenschein (admitted *pro hac vice*)  
Alaina M. Whitt (admitted *pro hac vice*)  
COVINGTON & BURLING LLP  
One CityCenter, 850 Tenth Street, NW  
Washington, DC 20001  
Tel.: (202) 662-6000 / Fax: (202) 662-6291  
Email: csipes@cov.com, estole@cov.com,  
mkennedy@cov.com, mkeane@cov.com,  
esonnenschein@cov.com, awhitt@cov.com

*Attorneys for Plaintiffs Amarin Pharma, Inc. and  
Amarin Pharmaceuticals Ireland Limited*

/s/ John P. Desmond  
John P. Desmond (Nev. Bar No. 5618)  
Brian R. Irvine (Nev. Bar No. 7758)  
DICKINSON WRIGHT PLLC  
100 West Liberty St., Suite 940  
Reno, NV 89501  
Tel: (775) 343-7500 / Fax: (775) 786-0131  
E-mail: jdesmond@dickinsonwright.com,  
birvine@dickinsonwright.com  
  
J.C. Rozendaal (admitted *pro hac vice*)  
Michael E. Joffre (admitted *pro hac vice*)  
Chandrika Vira (admitted *pro hac vice*)  
STERNE KESSLER, GOLDSTEIN & FOX PLLC  
1100 New York Ave., NW, Suite 600  
Washington, DC 20005  
Tel: (202) 371-2600 / Fax: (202) 371-2540  
E-mail: jcrozendaal@skgf.com, joffre@skgf.com,  
cvira@skgf.com

*Attorneys for Defendant Teva Pharmaceuticals USA, Inc.*